^
    Apply
    A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A72) (NCT03260322)
    Phase 1
    Astellas Pharma Global Development, Inc.
    Completed
    Last update posted :
    11/13/2024
    Initiation :
    09/08/2017
    Primary completion :
    05/10/2022
    Completion :
    05/10/2022
    EGFR • ALK
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP8374
    Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors (NCT03945253)
    Phase 1
    Astellas Pharma Inc
    Completed
    Last update posted :
    05/25/2021
    Initiation :
    08/05/2019
    Primary completion :
    06/12/2020
    Completion :
    06/12/2020
    EGFR • ALK
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    ASP8374